<SEC-DOCUMENT>0001683168-19-003151.txt : 20191003
<SEC-HEADER>0001683168-19-003151.hdr.sgml : 20191003
<ACCEPTANCE-DATETIME>20191003083113
ACCESSION NUMBER:		0001683168-19-003151
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191002
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191003
DATE AS OF CHANGE:		20191003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		191134462

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-100219.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>October 2, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 3, 2019, Aethlon Medical, Inc. (the &ldquo;Company&rdquo;) announced that Nasdaq has granted the Company an extension of
time to regain compliance with the exchange&rsquo;s continued listing requirement of a minimum $2.5 million of stockholders&rsquo;
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
extension is conditional upon the Company completing a reverse stock split and trading at or above Nasdaq&rsquo;s minimum $1.00
bid price requirement for a period of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder
approval of the reverse stock split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this
requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the minimum bid price requirement is met by October 29, 2019, then Nasdaq has allowed until the filing of the Company&rsquo;s December
31, 2019 Report on Form 10-Q, to be filed no later than February 14, 2020, to evidence compliance with Nasdaq&rsquo;s minimum stockholders&rsquo;
equity threshold, subject to reporting to Nasdaq prior to that time on the Company&rsquo;s fund raising progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_ex9901.htm">Press Releases dated October 3, 2019.</A></FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: October 3, 2019</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 93px; width: 225px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Aethlon
Medical Receives Extension from Nasdaq to Regain</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Compliance with Continued Listing Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO (October 3, 2019) &ndash; Aethlon
Medical, Inc. (<B>Nasdaq: AEMD</B>), a therapeutic technology company focused on unmet needs in global health, announced today
that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange&rsquo;s continued
listing requirement of a minimum $2.5 million of stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This extension is conditional upon Aethlon
Medical completing a reverse stock split and trading at or above Nasdaq&rsquo;s minimum $1.00 bid price requirement for a period
of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder approval of the reverse stock
split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the minimum bid price requirement is
met by October 29, 2019, then Nasdaq has allowed until the filing of Aethlon Medical&rsquo;s December 31, 2019 Report on Form 10-Q,
to be filed no later than February 14, 2020, to evidence compliance with Nasdaq&rsquo;s minimum stockholders&rsquo; equity threshold,
subject to reporting to Nasdaq prior to that time on Aethlon Medicals&rsquo; fund raising progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. is focused on addressing unmet needs in
global health. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier&reg; depletes the presence of circulating tumor-derived exosomes that promote immune
suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA
designated &quot;Breakthrough Device&quot; related to the treatment of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which
is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; &ldquo;potentially&rdquo;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to successfully meet the minimum bid
price and minimum stockholders&rsquo; equity requirements of the Nasdaq Capital Market, or any other national securities exchange,
and other risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption &quot;Risk
Factors&quot; in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings
with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the
Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proxy Voting Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="NewCo Signature3 (002)" STYLE="height: 42px; width: 146px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19 Old Kings Highway S. &ndash; Suite 210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Darien, CT 06820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toll Free (877) 972-0090</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Banks and Brokers call collect (203) 972-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@investor-com.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" != .$# 2(  A$! Q$!_\0
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M;,Z"BD!S169H+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  J )(# 2(  A$! Q$!_\0
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M^2Y6>8A@JD]\$]@,"NK\):1/I_@NRTS4H0)4B:.6/<".2>,CV-;6ZX_N1?\
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/SMD<V%N3U\M?Y44 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
